Dermapharm Holding
DMP.DE Mid CapHealthcare · Drug Manufacturers - Specialty & Generic
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Dermapharm Holding en bref
Dermapharm Holding (DMP.DE) is currently trading at 41,00 € with a market capitalization of 1,8 Md €. The trailing P/E ratio stands at 15.3x, with a forward P/E of 14.01x. The 52-week range spans from 31,70 € to 51,90 €; the current price is 21% below the yearly high. Year-over-year revenue growth stands at +1.3%. The net profit margin stands at 12.2%.
💰 Dividende
Dermapharm Holding pays an annual dividend of 0,88 € per share, representing a yield of 2.15%. The payout ratio stands at 33.58%.
📊 Avis des analystes
4 analystes évaluent Dermapharm Holding (DMP.DE) au consensus : None. L'objectif de cours moyen est de 50,38 €, soit un potentiel de +22.87% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 44,00 € à 60,00 €.
Dermapharm Holding : la thèse d'investissement en détail
Dermapharm Holding (DMP.DE) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in Germany. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Earnings growth of 35.5% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 65.49%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.
Le scénario baissier
Revenue growth has slowed to just 1.3%, which is below nominal GDP — the business is no longer outgrowing the broader economy.
À surveiller
- The analyst consensus price target implies 22.87% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Rentabilité élevée des capitaux propres (20.8% ROE)
- Marge brute élevée de 65.49% — signe d'un pouvoir de fixation des prix
- Actuellement jugée sous-évaluée
- Rendement du dividende solide de 2.15%
- Free cash flow positif
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior, higher leverage relative to equity.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Dermapharm Holding?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news